Sex steroids, Sleep, Body Fat, and Plasma Triglycerides in Women

血浆甘油三酯（TG）浓度升高是代谢异常的常见特征 与肥胖有关，也是心血管疾病的主要危险因素。肥胖是一个主要的危险因素， 两种情况似乎在妇女中的流行率增加：多囊卵巢综合征（PCOS） 睡眠呼吸紊乱PCOS影响5-8%的女性。睡眠呼吸障碍影响高达 10%的女性。阻塞性睡眠呼吸暂停（OSA）是睡眠呼吸障碍最常见的原因 尤其是在患有PCOS的肥胖女性中（约50%）。PCOS和OSA都增加了 血浆TG浓度与肥胖相关，以及PCOS和OSA对血浆TG的影响 浓度似乎是加性的。多囊卵巢综合征的不良反应的机制， OSA对血浆TG代谢的影响尚不清楚。因此，本项目的主要目标是确定 PCOS肥胖妇女血浆TG浓度升高的机制， 阻塞性睡眠呼吸暂停综合症。我们的一般假设是，PCOS的特征性激素环境的改变 （高雄激素血症和孕酮缺乏症）和OSA（高皮质醇血症），至少部分地， 在患有PCOS和OSA的肥胖女性中，TG是导致血浆TG浓度升高的原因。 此外，我们假设激素畸变，PCOS和OSA的特征， 尤其是对肥胖的女性有害，而不是瘦的女性。为了验证我们的假设，我们将测量 肝脏VLDL-TG和VLDL-apoB-100分泌率、VLDL-TG血浆清除率以及 可能影响VLDL-TG血浆清除（即，VLDL-apoC-II、VLDL-apoC-III、 在四组受试者中：i）患有OSA的肥胖女性（但不是PCOS）; ii）患有PCOS的肥胖女性 (but非OSA）; iii）无PCOS或OSA的肥胖女性;和iv）无PCOS或OSA的瘦女性，两者均 干预前后血浆睾酮、孕酮和糖皮质激素的变化 空房的更好地理解血浆TG稳态的机制可能会导致 为患有OSA和PCOS的女性提供更有效的治疗策略。

Increased plasma triglyceride (TG) concentration is a common feature of the metabolic abnormalities associated with obesity and a major risk factor for cardiovascular disease. Obesity is a major risk factor for two conditions that appear to be increasing in prevalence in women: the polycycstic ovary syndrome (PCOS) and sleep disordered breathing. PCOS affects 5-8% of women. Sleep disordered breathing affects up to 10% of women. Obstructive sleep apnea (OSA) is the most common cause for sleep disordered breathing and particularly prevalent in obese women with PCOS (~50%). Both PCOS and OSA augment the increase in plasma TG concentration associated with obesity, and the effects of PCOS and OSA on plasma TG concentration appear to be additive. The mechanisms responsible for the adverse effects of PCOS and OSA on plasma TG metabolism are not known. The primary goal of this project, therefore, is to determine the mechanisms responsible for the increase in plasma TG concentration in obese women with PCOS and OSA. It is our general hypothesis that alterations in the hormonal milieu that are characteristic of PCOS (hyperandrogenemia and progesterone deficiency) and OSA (hypercortisolemia) are, at least in part, responsible for the increase in plasma TG concentration in obese women with PCOS and OSA. Furthermore, we hypothesize that the hormonal aberrations, characteristic of PCOS and OSA, are particularly harmful to obese, compared with lean, women. To test our hypotheses, we will measure the rates of hepatic VLDL-TG and VLDL-apoB-100 secretion, VLDL-TG plasma clearance rate, and factors that may affect VLDL-TG plasma clearance (i.e., the concentrations of VLDL-apoC-ll, VLDL-apoC-lll, VLDL- apoE) in four groups of subjects: i) obese women with OSA (butnot PCOS); ii) obese women with PCOS (but not OSA); iii)obese women without PCOS or OSA; and iv) lean women without PCOS or OSA, both before and after interventions that will alter plasma testosterone, progesterone, and glucocorticoid availability. A better understanding of the mechanisms responsible for plasma TG homeostasis could lead to more effective treatment strategies for women with OSA and PCOS.